Qiagen NV

NL

QIA

Health Care

41.22 ₽

Current price

Strong sell
41.22 ₽

Target price 00%

Ranks rating

76

  • Position in sub-industry

    150 / 240

  • Position in country

    189 / 223

  • Return on Assets, %

    5.5

    -2.7

  • Net income margin, %

    19.1

    -6.7

  • EBITDA margin, %

    33.9

    5.6

  • Debt to Equity, %

    39.6

    15.1

  • Intangible assets and goodwill, %

    49

    4.7

  • Revenue CAGR 3Y, %

    1.6

    12.8

  • Total Equity change 1Y, %

    9.8

    -2.4

  • Revenue Y, % chg

    -8.3

    0

  • P/E

    26.3

    32.1

  • P/BV

    2.3

    2

  • P/S

    4.5

    4.1

  • EV/S

    4.7

    3.6

  • EV/EBITDA

    14.3

    7.8

  • Average Analyst recommendation

    Hold

    Hold

  • Average upside forecasts, %

    24.4

    48.9

  • Forward P/E

    18.5

    25.5

  • Expected dividend per share

    0

    0

  • Payout Ratio, %

    0

    10.1

  • Dividend Ex Date

    2024-01-30

Get an analytical review of this company

Competitors

Ranks

  • Lonza Group AG

    00%

  • Samsung Biologics Co Ltd

    00%

  • IQVIA Holdings Inc

    00%

  • West Pharmaceutical Services Inc

    00%

  • Agilent Technologies Inc

    00%

  • Thermo Fisher Scientific Inc

    00%

  • Danaher Corp

    00%

  • Qiagen NV

    00%

  • Mettler-Toledo International Inc

    00%

  • Sartorius Stedim Biotech SA

    00%

Ready-made portfolio of the best Russian stocks

  • Created by artificial intelligence
  • Verified by analysts
  • Available even to beginners

Company information

  • Country

    Netherlands

  • Sector

    Health Care

  • Industry group

    Pharmaceuticals, Biotechnology & Life Sciences

  • Industry

    Life Sciences Tools & Services

  • Sub-sector

    Health Care

  • Capitalization (millions of $)

    8894.1

  • Ticker

    QGEN.K

  • ISIN

    NL0015001WM6

  • IPO date

    1996-09-01

  • Availability on Russian exchanges

    Yes

  • Reporting for

    2024-03-11

  • Date fact. publication of reports

    2023-12-31

Company Description

Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.